PSA levels and the probability of prostate cancer on biopsy

Matthew B Gretzer, Alan W. Partin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives: Approaches to screening for prostate cancer have continued to be refined since the introduction of prostate-specific antigen (PSA). Since the introduction of PSA, increasing numbers of patients are presenting solely with an elevated PSA, and palpably normal prostate gland. As newer understanding emerges regarding the meaning of an isolated PSA elevation, urologists are becoming more enabled to counsel their patients and project a more accurate prediction of the likelihood of cancer on biopsy. The following will be a review of PSA in determining the presence of cancer on biopsy. Methods: PubMed and Medline literature searches as well as bibliographic reviews of published peer reviewed journals were performed to select articles regarding PSA and screening for prostate cancer. Relevant articles were reviewed and the data summarized as they pertain to interpreting PSA levels and predicting the presence of prostate cancer. Results: Widespread use of PSA for early detection has resulted in clinical stage Tlc becoming the most prevalent presenting stage. For values of PSA between 4.0 and 10.0 ng/ml, there exist a 22-27% likelihood of cancer, while those above 10 ng/ml yield up to a 67% chance of cancer. It must be stressed that DRE must be combined with interpretation of PSA as up to 25% of men with prostate cancer have PSA levels within the normal range 0-4 ng/ml. Conclusions: Evaluation of PSA in the context of prostate volume (PSAD), velocity (PSAV), and age-specific reference ranges, percent-free PSA, and predictive nomograms combining values have allowed for more accurate prediction of the likelihood of prostate cancer prior to biopsy.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalEuropean Urology, Supplement
Volume1
Issue number6
DOIs
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biopsy
Prostate
Neoplasms
Reference Values
Nomograms
Peer Review
PubMed

Keywords

  • Age-specific PSA
  • BPH
  • DRE
  • Percent-free PSA
  • PSA
  • PSAD
  • PSAV

ASJC Scopus subject areas

  • Urology

Cite this

PSA levels and the probability of prostate cancer on biopsy. / Gretzer, Matthew B; Partin, Alan W.

In: European Urology, Supplement, Vol. 1, No. 6, 09.2002, p. 21-27.

Research output: Contribution to journalArticle

@article{c237772df78b470d9e3db5f7d96c8c13,
title = "PSA levels and the probability of prostate cancer on biopsy",
abstract = "Objectives: Approaches to screening for prostate cancer have continued to be refined since the introduction of prostate-specific antigen (PSA). Since the introduction of PSA, increasing numbers of patients are presenting solely with an elevated PSA, and palpably normal prostate gland. As newer understanding emerges regarding the meaning of an isolated PSA elevation, urologists are becoming more enabled to counsel their patients and project a more accurate prediction of the likelihood of cancer on biopsy. The following will be a review of PSA in determining the presence of cancer on biopsy. Methods: PubMed and Medline literature searches as well as bibliographic reviews of published peer reviewed journals were performed to select articles regarding PSA and screening for prostate cancer. Relevant articles were reviewed and the data summarized as they pertain to interpreting PSA levels and predicting the presence of prostate cancer. Results: Widespread use of PSA for early detection has resulted in clinical stage Tlc becoming the most prevalent presenting stage. For values of PSA between 4.0 and 10.0 ng/ml, there exist a 22-27{\%} likelihood of cancer, while those above 10 ng/ml yield up to a 67{\%} chance of cancer. It must be stressed that DRE must be combined with interpretation of PSA as up to 25{\%} of men with prostate cancer have PSA levels within the normal range 0-4 ng/ml. Conclusions: Evaluation of PSA in the context of prostate volume (PSAD), velocity (PSAV), and age-specific reference ranges, percent-free PSA, and predictive nomograms combining values have allowed for more accurate prediction of the likelihood of prostate cancer prior to biopsy.",
keywords = "Age-specific PSA, BPH, DRE, Percent-free PSA, PSA, PSAD, PSAV",
author = "Gretzer, {Matthew B} and Partin, {Alan W.}",
year = "2002",
month = "9",
doi = "10.1016/S1569-9056(02)00053-2",
language = "English (US)",
volume = "1",
pages = "21--27",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - PSA levels and the probability of prostate cancer on biopsy

AU - Gretzer, Matthew B

AU - Partin, Alan W.

PY - 2002/9

Y1 - 2002/9

N2 - Objectives: Approaches to screening for prostate cancer have continued to be refined since the introduction of prostate-specific antigen (PSA). Since the introduction of PSA, increasing numbers of patients are presenting solely with an elevated PSA, and palpably normal prostate gland. As newer understanding emerges regarding the meaning of an isolated PSA elevation, urologists are becoming more enabled to counsel their patients and project a more accurate prediction of the likelihood of cancer on biopsy. The following will be a review of PSA in determining the presence of cancer on biopsy. Methods: PubMed and Medline literature searches as well as bibliographic reviews of published peer reviewed journals were performed to select articles regarding PSA and screening for prostate cancer. Relevant articles were reviewed and the data summarized as they pertain to interpreting PSA levels and predicting the presence of prostate cancer. Results: Widespread use of PSA for early detection has resulted in clinical stage Tlc becoming the most prevalent presenting stage. For values of PSA between 4.0 and 10.0 ng/ml, there exist a 22-27% likelihood of cancer, while those above 10 ng/ml yield up to a 67% chance of cancer. It must be stressed that DRE must be combined with interpretation of PSA as up to 25% of men with prostate cancer have PSA levels within the normal range 0-4 ng/ml. Conclusions: Evaluation of PSA in the context of prostate volume (PSAD), velocity (PSAV), and age-specific reference ranges, percent-free PSA, and predictive nomograms combining values have allowed for more accurate prediction of the likelihood of prostate cancer prior to biopsy.

AB - Objectives: Approaches to screening for prostate cancer have continued to be refined since the introduction of prostate-specific antigen (PSA). Since the introduction of PSA, increasing numbers of patients are presenting solely with an elevated PSA, and palpably normal prostate gland. As newer understanding emerges regarding the meaning of an isolated PSA elevation, urologists are becoming more enabled to counsel their patients and project a more accurate prediction of the likelihood of cancer on biopsy. The following will be a review of PSA in determining the presence of cancer on biopsy. Methods: PubMed and Medline literature searches as well as bibliographic reviews of published peer reviewed journals were performed to select articles regarding PSA and screening for prostate cancer. Relevant articles were reviewed and the data summarized as they pertain to interpreting PSA levels and predicting the presence of prostate cancer. Results: Widespread use of PSA for early detection has resulted in clinical stage Tlc becoming the most prevalent presenting stage. For values of PSA between 4.0 and 10.0 ng/ml, there exist a 22-27% likelihood of cancer, while those above 10 ng/ml yield up to a 67% chance of cancer. It must be stressed that DRE must be combined with interpretation of PSA as up to 25% of men with prostate cancer have PSA levels within the normal range 0-4 ng/ml. Conclusions: Evaluation of PSA in the context of prostate volume (PSAD), velocity (PSAV), and age-specific reference ranges, percent-free PSA, and predictive nomograms combining values have allowed for more accurate prediction of the likelihood of prostate cancer prior to biopsy.

KW - Age-specific PSA

KW - BPH

KW - DRE

KW - Percent-free PSA

KW - PSA

KW - PSAD

KW - PSAV

UR - http://www.scopus.com/inward/record.url?scp=0036765809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036765809&partnerID=8YFLogxK

U2 - 10.1016/S1569-9056(02)00053-2

DO - 10.1016/S1569-9056(02)00053-2

M3 - Article

AN - SCOPUS:0036765809

VL - 1

SP - 21

EP - 27

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 6

ER -